Abstract 6000: Clinical Outcome for the Endothelial Progenitor Cells Capturing Genous Stent: First Results of the 1-Year Follow-Up in 5000 Patients
Background: Although drug-eluting coronary stents (DES) are an important medical innovation reducing clinically relevant restenosis, late and very late stent thrombosis due to the DES-inherent delayed endothelialization, is a continuous concern. Therefore a new stent was developed to even enhance the speed of endothelialization by endothelial progenitor cells capturing (EPCC) with a layer of murine, monoclonal, antihuman CD34 antibody.
Methods: The e-healing registry enrollment was 5000 pats worldwide in 144 sites. Based on previous results, patients should be preferably on pretreatment with statins to enhance EPCC process. Dual antiplatelet therapy was recommended for 1 month.
Results: The following data are derived from the first 1640 pats evaluated. Mean age of the pats was 62.8 y with 78.7% males. 25% were diabetics, 68,3% hypertensives and 24.8% current smokers. Previous MI was present in 36.7%. Stable angina was reported in 43.3%, ACS in 42,3% and silent ischemia in 14.4%. 97.7% of the treated lesions were de-novo with type B2/C lesions in 49.1%. 73.8% of pats were on statins before EPCC stent implantation. In diabetic patients, clinically driven TLR after 1 year was 4.7% and MACE 10.3% with a late ST rate of 1.1%.
Conclusions: In this first world wide registry of the CE-approved endothelial progenitor cells capturing stent, it appears to be very safe, even in diabetic patients. After 1 year, clinically driven TLR and late stent thrombosis were remarkably low, making this new stent a possible alternative to DES with no need for prolonged dual antiplatelet therapy.